BioAge Labs (BIOA) just posted its FY 2025 third quarter numbers, reporting revenue of US$2.1 million and a basic EPS loss of US$0.56, alongside a net loss of US$20.2 million, keeping the story firmly in loss-making territory. Over recent quarters, revenue has moved from US$0 million in Q4 2024 to US$1.5 million in Q1 2025 and US$2.4 million in Q2 2025. Quarterly basic EPS has remained in loss-per-share territory between US$0.36 and US$0.60, which keeps the focus on the pace at which losses are being absorbed. For investors watching a business still in development mode, the current print underlines that margins remain pressured and the path to cleaner profitability remains the key debate.
See our full analysis for BioAge Labs.With the headline numbers on the table, the next step is to see how this earnings profile lines up against the widely held narratives around BIOA's growth potential, risk profile and long term margin story.
Curious how numbers become stories that shape markets? Explore Community Narratives
US$75.8 million loss over the last year
- On a trailing twelve month basis to Q3 FY 2025, BIOA recorded a net loss of US$75.8 million on revenue of US$5.9 million, so the business is still firmly in heavy investment mode.
- Critics highlight the bearish view that BIOA is unprofitable and forecast to stay that way for at least three years, and the current numbers line up with that concern:
- The trailing twelve month net loss of US$75.8 million compares with quarterly net losses between US$12.9 million and US$23.4 million across the last six reported quarters, so the company has not yet shown a move toward breakeven in this period.
- Forecasts also point to average earnings declines of 33.8% per year over the next three years, which fits with a pattern of ongoing losses rather than a quick shift toward profitability.
Revenue expected to fall 93.7% a year
- While revenue has reached US$2.1 million in Q3 FY 2025 and US$5.9 million over the last twelve months, forecasts in the supplied data point to a very large revenue decline of 93.7% per year over the next three years.
- What is striking for the bearish narrative is how this forecasted revenue drop contrasts with the recent ramp from US$0 to quarterly revenues above US$1 million:
- Reported revenue progressed from US$0 in Q4 FY 2024 to US$1.5 million in Q1, US$2.4 million in Q2 and US$2.1 million in Q3 FY 2025, yet the forecast still points to sharp declines ahead rather than a continuation of this ramp.
- Because margins remain loss making at every step, any slowdown or fall in revenue would leave the existing net loss profile, including the US$20.2 million loss this quarter and US$75.8 million over the last year, as a key focus for cautious investors.
Valuation sits between peers and the sector
- BIOA currently trades at a P/B of 2.4x, which is cheaper than the cited peer average of 3.9x, but more expensive than the broader US Pharmaceuticals industry at 2.1x, so investors are paying a middle of the pack multiple for a business that is still loss making.
- Supporters and skeptics both point to this mixed valuation signal when weighing the risk profile:
- On one hand, the 2.4x P/B is below peers, which some readers may see as room for upside if BIOA eventually narrows its trailing twelve month loss of US$75.8 million or stabilizes revenue beyond the forecast 93.7% yearly decline.
- On the other hand, the same 2.4x P/B sits above the 2.1x industry average while the company remains unprofitable, which ties in with concerns about recent shareholder dilution and share price volatility flagged in the risk summary.
To see how other investors are connecting these numbers to longer term stories, check out the broader discussion around BioAge Labs via Curious how numbers become stories that shape markets? Explore Community Narratives.
Next Steps
Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on BioAge Labs's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.
If the mixed signals here leave you unsure, that can be a useful starting point. Move quickly, review the details, and weigh them against the company's 4 important warning signs.
See What Else Is Out There
BIOA is posting relatively small revenue against sizeable net losses, with forecasts pointing to ongoing losses and a pressured path toward profitability.
If you want ideas where the risk profile looks tighter and the balance sheet is a stronger anchor, check out the 73 resilient stocks with low risk scores to compare alternatives right now.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com